Overview

Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin

Status:
Unknown status

Trial end date:
2018-10-01

Target enrollment:

Participant gender:

Summary

The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Ain Shams Maternity Hospital

Treatments:

Metformin